pharmaceuticals

Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling. Short sellers could be looking to close out their position and can face a loss if they have to...

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains. The year witnessed some watershed regulatory...

Pfizer, Inc. (NYSE: PFE) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA...

Moderna Inc (NASDAQ: MRNA) shares are trading lower Wednesday and are falling toward a support level. The stock was trending on social media sites throughout the day after the stock saw some movement. Moderna was down 6.26% at $251.36 at market close Wednesday. See Also: What's Going...

The year 2021 has featured retail trading-induced short squeezes, soaring special purpose acquisition companies (SPACs) and extreme volatility in cryptocurrency markets. Amid the many bouts of short-term mania, there are a handful of stocks in the S&P 500 Index that...

Pfizer Inc. (NYSE: PFE) shares are trading higher Monday after the company announced it will acquire Arena Pharmaceuticals Inc (NASDAQ:ARNA) for $100 per share. UBS analyst Colin Bristow also upgraded the stock from Neutral to Buy and raised the price...

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way. Catalyst’s...

The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In fact, 65 stocks in the S&P 500 are currently in the red year-to-date in 2021. When a stock struggles in a bull...

Royal Caribbean Cruises Ltd (NYSE: RCL) soared more than 10% higher at one point on Friday after Pfizer Inc. (NYSE: PFE) said its experimental antiviral COVID-19 pill, PAXLOVID™, reduced the risk of hospitalization or death by 89% and it plans to submit the data to the FDA for Emergency...

Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc (NASDAQ: CRTX) reported Phase 2/3 GAIN trial data for its Alzheimer’s disease trial. The company stated co-primary endpoints were...

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to safety issues. Following the suspension of this promising pipeline, the company’s growth recovery prospects appear dismal, according to BofA Securities. The...

Moderna Inc (NASDAQ: MRNA) stock is trading at its lowest level since late July. This once high-flying stock that notched up stratospheric gains from its COVID-19 program has lost altitude. The Breathtaking Tally Hits The Pause: Moderna shares soared over 430% in 2020...

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Friday as most COVID-19-related biopharma stocks dropped. The weakness was partly due to the broader market sell-off, triggered by higher bond yields and expectations of removal of monetary policy accommodation. Novavax was down 16.94% at $172....

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower Thursday, although there looks to be no company-evident news to explain the jump in share price. The stock was trending throughout the day on social media sites such as StockTwits. ChemoCentryx was down 12.41% at $17.13 at last...

Sanofi SA (NASDAQ: SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outperform and raised his price target per U.S. ADR from $69.61 to $71.37. Related Link: Cigna Has...